<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568749</url>
  </required_header>
  <id_info>
    <org_study_id>A2750596</org_study_id>
    <nct_id>NCT01568749</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations</brief_title>
  <official_title>A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study investigating the pharmacokinetic profiles of four extended release paracetamol&#xD;
      formulations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</measure>
    <time_frame>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</measure>
    <time_frame>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Standard paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Standard paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 1</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol Formulation 2</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 3</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 4</intervention_name>
    <description>paracetamol</description>
    <arm_group_label>Formulation 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent:Demonstrates understanding of the study and willingness to participate as&#xD;
             evidenced by voluntary written informed consent and has received a signed and dated&#xD;
             copy of the informed consent form.&#xD;
&#xD;
          -  Age:Aged 18 to 50 years inclusive.&#xD;
&#xD;
          -  Body Mass Index (BMI):Body Mass Index must be in the range 19 - 28 kg/m2.&#xD;
&#xD;
          -  Compliance:Understands and is willing, able and likely to comply with all study&#xD;
             procedures and restrictions.&#xD;
&#xD;
          -  General Health:Good general health with (in the opinion of the investigator) no&#xD;
             clinically significant and relevant abnormalities of medical history or physical&#xD;
             examination.&#xD;
&#xD;
          -  Contraception:Females of childbearing potential who are, in the opinion of the&#xD;
             investigator, practicing a reliable method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy:Women who are pregnant or who have a positive serum pregnancy test.&#xD;
&#xD;
          -  Breast-feeding:Women who are breast-feeding.&#xD;
&#xD;
          -  Allergy/Intolerance:Known or suspected intolerance or hypersensitivity to the study&#xD;
             materials (or closely related compounds) or any of their stated ingredients.&#xD;
&#xD;
          -  Clinical Study/Experimental Medication:a) Participation in another clinical study or&#xD;
             receipt of an investigational drug within 30 days of the screening visit. b) Previous&#xD;
             participation in this study.&#xD;
&#xD;
          -  Substance abuse:Recent history (within the last 5 years) of alcohol or other substance&#xD;
             abuse.&#xD;
&#xD;
          -  Personnel:An employee of the sponsor or the study site or members of their immediate&#xD;
             family.&#xD;
&#xD;
          -  Disease: a) Current or recurrent disease that could affect the action, absorption or&#xD;
             disposition of the study medication or clinical or laboratory assessments (e.g.&#xD;
             hepatic disorders, renal insufficiency, congestive heart failure). b) Current or&#xD;
             relevant previous history of serious, severe or unstable physical or psychiatric&#xD;
             illness, any medical disorder that may require treatment or make the subject unlikely&#xD;
             to fully complete the study, or any condition that presents undue risk from the study&#xD;
             medication or procedures.&#xD;
&#xD;
          -  Vegetarians:Subjects who are vegetarian.&#xD;
&#xD;
          -  Hepatitis and HIV Screening:Positive screening for Serum Hepatitis B Surface Antigen,&#xD;
             Hepatitis C or Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Medications:Current (within 14 days of screening) or regular use of any prescription,&#xD;
             OTC, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the&#xD;
             30 days prior to dosing, (e.g. barbiturates, theophylline, cimetidine, or&#xD;
             erythromycin).&#xD;
&#xD;
          -  Smoking:Non-smokers of less than 3 months or current use of nicotine-containing&#xD;
             products.&#xD;
&#xD;
          -  Blood:Subject has donated or experienced significant blood loss within 56 days of&#xD;
             Visit 2, donated plasma within 7 days of Visit 2, or has a hemoglobin value of = 12.0&#xD;
             g/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services ARIZONA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>otc</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Paracetamol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

